iiinova — where your digital self keeps evolving

David Collister @turbodc.bsky.social · 13/01/2026

This should be criminal because it’s puts patients actually enrolled in the trial at risk without any potential benefit due to an unpowered trial due to enrolling patients without the disease and non-adherence. Shame on this involved.

062

Reposted by David Collister

Oxford Population Health @oxpop.bsky.social · 25/11/2025

🎉Over 300 sites are now collaborating in the EASi-KIDNEY trial! 📉EASi-KIDNEY will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD) ➡️ buff.ly/PXTVVeE

032

Reposted by David Collister

Michael Hendricks 🇨🇦 @michaelhendricks.bsky.social · 30/10/2025

Canadian researchers should be aware the there is a motion before the Parliamentary Standing Committee on Science and Research to force Tricouncils to hand over disaggregated peer review data on all applications: Applicant names, profiles, demographics Reviewers names, profiles, comments, and scores

13143168

David Collister @turbodc.bsky.social · 29/10/2025

All we have here in Canada is low dose Testing prednisone then MMF 😔 once the proteinuria rebounds Putting these patients in ASI trials locally too

220

David Collister @turbodc.bsky.social · 25/10/2025

Do you use steroidal MRAs if you don’t have access to a finerenone or aldosterone synthase inhibitor trial?

120

David Collister @turbodc.bsky.social · 25/09/2025

Dr. Moorthy reviewing the WHO global action plan for clinical trial ecosystem strengthening at the 4th Annual ACT meeting in Cape Breton, NS. We are making progress in Canada but lots of work to do! @cvcualberta.bsky.social @csnscn.bsky.social @ualberta.bsky.social

111

David Collister @turbodc.bsky.social · 03/09/2025

The percentage in the placebo arm reflects that potassium fluctuations in HD are common related to missed dialysis, diet and other factors. Other takeaway is that hyperkalemia is manageable and typically harm patients.

011

David Collister @turbodc.bsky.social · 03/09/2025

I think we are all excited to see how to anti-inflammatory hypothesis pans out over the next couple of years as well

000

David Collister @turbodc.bsky.social · 03/09/2025

And stayed tuned for some secondary papers in addition to the ones already published on run-in adherence assessment (study within a trial) and heart failure event definitions in dialysis RCTs (meta-epidemiological)

163

David Collister @turbodc.bsky.social · 03/09/2025

Late to the party but important takeaways: large publically funded international trials are feasible in dialysis, run-ins are great, low dose spironolactone is safe and consider it’s use in HFrEF in dialysis or PD for low K+ or for volume, we don’t believe the sex subgroup analysis #NephJC

2134

David Collister @turbodc.bsky.social · 16/08/2025

Some really interesting stories in this one!

020

David Collister @turbodc.bsky.social · 30/07/2025

Local approach in the couple of places I’ve practiced in Canada is to intensify with daily HD because of the morbidity and mortality of calciphylaxis. Does this mean you would keep on PD if adequate MBD parameters? Could this be a domain in BEAT-Calci? I doubt given lack of equipoise.

121

David Collister @turbodc.bsky.social · 23/07/2025

When I order eGFR cys it’s because I think eGFR Cr is falsely high or low and I have a clinical reason for this which I already know affects prognosis (e.g. cirrhosis, malignancy, neuromuscular disease, athlete). How was this accounted for?

000

David Collister @turbodc.bsky.social · 09/07/2025

Would you accept 0.3mg po every other day over prednisone for “idiopathic” pericarditis?

110

David Collister @turbodc.bsky.social · 08/07/2025

What’s your treatment for idiopathic pericarditis in PD? NSAIDs will cause loss of RRF and risk of UGIB. Colchicine at even low doses=diarrhea (and myopathy/cytopenias). Prednisone or try colchicine 0.3-0.6mg po daily to see if tolerated? Defer to cardiology? @askrenal.bsky.social #askrenal

112

David Collister @turbodc.bsky.social · 27/06/2025

Great paper! Would like to see this work also done in Alberta where I suspect MRP, remuneration model, work up and evaluation process, access to weight loss programs and navigators all play a role.

020

Reposted by David Collister

CJKHD @cjkhd.bsky.social · 26/06/2025

In patients receiving #maintenancedialysis, there is substantial variability across the 4 steps required to receive a #kidneytransplant with the rate of referral varying almost 8-fold across Ontario’s Regional Renal Programs @lhsccanada.bsky.social @csnscn.bsky.social doi.org/10.1177/2054...

Figure 5 demonstrates the average number of steps completed toward receiving a kidney transplant which varied from 11.7 (95% CI: 9.3, 14.8) to 44.0 (95% CI: 38.6, 50.1) steps per 100 patient-years across RRPs.

121

Reposted by David Collister

CJKHD @cjkhd.bsky.social · 20/06/2025

Design of the international #ACHIEVE trial comparing spironolactone to placebo in over 2500 people receiving #dialysis for #kidneyfailure. @csnscn.bsky.social @cjkhd.bsky.social doi.org/10.1177/2054...

031

David Collister @turbodc.bsky.social · 01/05/2025

It was a pleasure to work with Dr. Adeera Levin on this JCI editorial re: the impact of gender affirming hormone therapy on blood/urine biomarkers and renal plasma flow/iohexol plasma GFR. Provides new insights to sex based differences in kidney function. pubmed.ncbi.nlm.nih.gov/40309772/

pubmed.ncbi.nlm.nih.gov

The differential effects of sex hormone therapy on kidney function: insights into biological sex differences - PubMed

There are known sex (i.e., biological) and gender (i.e., social) differences in the epidemiology and outcomes of chronic kidney disease. In this issue of the JCI, van Eeghen et al. provide a prospecti...

041

David Collister @turbodc.bsky.social · 01/05/2025

Really enjoyed writing this editorial on the PK of Sativex in healthy controls and CKD from Denmark with Brendan Smyth from Sydney: pubmed.ncbi.nlm.nih.gov/40303213/ Stay tuned for our PK study of oral THC/CBD (MPL-001) in CKD/dialysis @lastwalsh.bsky.social @csnscn.bsky.social @cntn

pubmed.ncbi.nlm.nih.gov

Searching for Fire Amid the Smoke: Will Cannabinoids Prove Useful and Safe for Those With CKD? - PubMed

Searching for Fire Amid the Smoke: Will Cannabinoids Prove Useful and Safe for Those With CKD?

000

David Collister @turbodc.bsky.social · 17/03/2025

I used this to find my current position. Definitely worth checking out, we have some fantastic institutions in Canada.

001

David Collister @turbodc.bsky.social · 24/02/2025

I think the only place that does bone biopsy in Canada is in Quebec! Wish we had it availability locally.

120

David Collister @turbodc.bsky.social · 24/02/2025

What’s the eGFR? 31 is probably different than 59 for the risk of adverse events. I don’t think I would have any concerns re: bisphosphonate but would monitor PTH more closely than usual and if it drops or there is an AE consider an alternative.

140

David Collister @turbodc.bsky.social · 17/02/2025

Agree with getting what you can on board ASAP

000

David Collister @turbodc.bsky.social · 08/02/2025

Here are our thoughts! www.kireports.org/article/S246...

kireports.org

001

David Collister @turbodc.bsky.social · 28/01/2025

Usually will start with LMWH then transition to 5mg po bid or 2.5mg po bid depending on weight/age with F/U anticoagulation clinic. I have never specifically loaded in dialysis.

010

David Collister @turbodc.bsky.social · 21/01/2025

Does it matter assuming they were already in ICU and could easily get norepinephrine? 🤫

110

David Collister @turbodc.bsky.social · 19/01/2025

Risk of potential cyst growth can cardiorenal benefits based on degree of albuminuria. It’s a tough one eh?

010

David Collister @turbodc.bsky.social · 18/01/2025

Would you randomize a patient with PKD and diabetes with albuminuria Swap?

100

David Collister @turbodc.bsky.social · 14/01/2025

65 year old male DM2 HFrEF on RAAS-i and SGLT2-i starts incremental PD with eGFR 7 for volume and uremic symptoms. A1C above target and RRF 1L. Do you keep them on SGLT2-i? You don’t have the luxury to randomize in RENAL-LIFECYCLE. @askrenal.bsky.social

111

David Collister @turbodc.bsky.social · 03/01/2025

We are currently working on an editorial 😊

020

David Collister @turbodc.bsky.social · 19/11/2024

Celebrating Kevin’s successful MSc defense (my 1st graduate student). Watch out for some papers re: SR/MA of screening for MCI/dementia in kidney disease and the representativeness of the elderly in dialysis RCTs. Thanks for Drs. Klarenbach, Thompson and Camicioli (committee) #UofA #AbSPORU

020